1 |
0.9% normal saline (control) |
- |
- |
- |
- |
299 1件: 299 💬 |
2 |
0.9% sodium chloride (normal saline) |
Chloride ion |
1件: D02056 D02056 💬 |
- |
- |
006 1件: 6 💬 |
3 |
10% metronidazole ointment |
Metronidazole |
3件: D00409 D00409, D05016 D05016, D05017 D05017 💬 |
- |
- |
096 1件: 96 💬 |
4 |
19 nor vitamin d |
Vitamin D |
- |
- |
- |
013 1件: 13 💬 |
5 |
: immunoglobulina umana normale 10% per somministrazione endovenosa |
- |
- |
- |
- |
014 1件: 14 💬 |
6 |
[18f]-(e)-n-(3-iodoprop-2-enyl)-2b-carbofluoroethoxy-3b-(4'-methylphenyl)nortropane |
- |
- |
- |
- |
006 1件: 6 💬 |
7 |
[18f]nos |
- |
- |
- |
- |
006 1件: 6 💬 |
8 |
A novel synthetic, orally-administered, non-peptide small molecule, which acts as |
- |
- |
- |
- |
254 1件: 254 💬 |
9 |
A-f-a-f (novorapid-fiasp-novorapid-fiasp) |
- |
- |
- |
- |
299 1件: 299 💬 |
10 |
Administration of a high dose of desipramine |
Desipramine |
2件: D00812 D00812, D07791 D07791 💬 |
SLC6A2 2件: SLC6A2, SLC6A4 💬 |
Serotonergic synapse 2件: Serotonergic synapse, Synaptic vesicle cycle |
156 1件: 156 💬 |
11 |
Administration of a low dose of desipramine |
Desipramine |
2件: D00812 D00812, D07791 D07791 💬 |
SLC6A2 2件: SLC6A2, SLC6A4 💬 |
Serotonergic synapse 2件: Serotonergic synapse, Synaptic vesicle cycle |
156 1件: 156 💬 |
12 |
Administration of an ace-inhibitor or not |
- |
- |
- |
- |
210 1件: 210 💬 |
13 |
Alk-001 (no generic name) |
- |
- |
- |
- |
301 1件: 301 💬 |
14 |
Amikin, amiklin, amicacin, bb-k8, biklin, fabianol, kaminax, mikavir, novamin, pierami |
- |
- |
- |
- |
299 1件: 299 💬 |
15 |
Amikin®, amiklin, amicacin, bb-k8, biklin®, fabianol®, kaminax, mikavir, novamin®, pierami |
- |
- |
- |
- |
299 1件: 299 💬 |
16 |
Amlodipine |
Amlodipine |
3件: D00615 D00615, D02914 D02914, D07450 D07450 💬 |
CACNA1C 4件: CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 |
Adrenergic signaling in cardiomyocytes 36件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy, Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
051 3件: 51, 67, 298 💬 |
17 |
Amlodipine (drug) |
Amlodipine |
3件: D00615 D00615, D02914 D02914, D07450 D07450 💬 |
CACNA1C 4件: CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 |
Adrenergic signaling in cardiomyocytes 36件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy, Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
298 1件: 298 💬 |
18 |
Amlodipine gel |
Amlodipine |
3件: D00615 D00615, D02914 D02914, D07450 D07450 💬 |
CACNA1C 4件: CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 |
Adrenergic signaling in cardiomyocytes 36件: Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy, Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
051 1件: 51 💬 |
19 |
Amoxicillin, metronidazole and tetracycline |
Amoxicillin |
7件: D00201 D00201, D00229 D00229, D00409 D00409, D02925 D02925, D05016 D05016, D05017 D05017, D07452 D07452 💬 |
- |
- |
097 1件: 97 💬 |
20 |
Atazanavir (atv) + ritonavir (rtv), continuation of backbone 2 nucleoside reverse transcriptase inhibitor (nrtis) |
Atazanavir |
3件: D00427 D00427, D01276 D01276, D07471 D07471 💬 |
- |
- |
265 1件: 265 💬 |
21 |
Atazanavir/ritonavir |
Atazanavir |
3件: D00427 D00427, D01276 D01276, D07471 D07471 💬 |
- |
- |
265 1件: 265 💬 |
22 |
Azithromycin + metronidazole |
Azithromycin |
6件: D00409 D00409, D02134 D02134, D05016 D05016, D05017 D05017, D06390 D06390, D07486 D07486 💬 |
- |
- |
096 1件: 96 💬 |
23 |
Aún no establecido |
- |
- |
- |
- |
053 1件: 53 💬 |
24 |
Behavioral: assessment of motor and non-motors symptoms of pd evaluation of hyper- and hypodopaminergic behaviors |
- |
- |
- |
- |
006 1件: 6 💬 |
25 |
Bia 9-1067 non-micronized |
BIA |
- |
- |
- |
006 1件: 6 💬 |
26 |
Bio-enhanced curcumin soft gelatin capsule |
Curcumin |
2件: D00115 D00115, D06892 D06892 💬 |
- |
- |
097 1件: 97 💬 |
27 |
Biological : i10e (human normal immunoglobulin for intravenous administration 100mg/ml) |
Human immunoglobulin G |
- |
- |
- |
014 1件: 14 💬 |
28 |
Biological: kiovig® (human normal immunoglobulin for intravenous administration 100mg/ml) |
Human immunoglobulin G |
- |
- |
- |
014 1件: 14 💬 |
29 |
Botox 200u in normal saline |
- |
- |
- |
- |
226 1件: 226 💬 |
30 |
Candesartan plus non-ccb agents |
Candesartan |
1件: D00522 D00522 💬 |
AGTR1 1件: AGTR1 💬 |
AGE-RAGE signaling pathway in diabetic complications 16件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway |
067 1件: 67 💬 |
31 |
Cas no.: 7758-16-9 |
- |
- |
- |
- |
166 1件: 166 💬 |
32 |
Catridecacog |
Catridecacog |
1件: D10532 D10532 💬 |
- |
- |
097 2件: 97, 288 💬 |
33 |
Celulas madre mesenquimales troncales adultas alogenicas de médula ósea no expandida |
- |
- |
- |
- |
274 1件: 274 💬 |
34 |
Clarithromycin (not used as of 4/2020) |
Clarithromycin |
1件: D00276 D00276 💬 |
- |
- |
006 1件: 6 💬 |
35 |
Coenzyme q-10 in normal control subjects |
Ubidecarenone |
1件: D01065 D01065 💬 |
- |
- |
086 1件: 86 💬 |
36 |
Control intervention (no dexamethasone) |
Dexamethasone |
9件: D00292 D00292, D00975 D00975, D01510 D01510, D01615 D01615, D01632 D01632, D01948 D01948, D02174 D02174, D02591 D02591, D02592 D02592 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
046 1件: 46 💬 |
37 |
Corticosteroid and non-biological agents. |
- |
- |
- |
- |
046 1件: 46 💬 |
38 |
Cysteine |
Cysteine |
2件: D00026 D00026, D02326 D02326 💬 |
- |
- |
006 11件: 6 , 13, 19, 34, 84, 85, 88, 90, 254, 296, 310 💬 |
39 |
Cysteine hydrochloride |
Cysteine |
2件: D00026 D00026, D02326 D02326 💬 |
- |
- |
254 1件: 254 💬 |
40 |
Células mesenquimales troncales adultas alogénicas de médula ósea no expandidas |
- |
- |
- |
- |
274 1件: 274 💬 |
41 |
Células mesenquimales troncales adultas alogénicas de médula ósea no expandidas(ref cruzada pei nº 12-088) |
- |
- |
- |
- |
274 1件: 274 💬 |
42 |
Ddavp (desmopressin) |
Desmopressin |
2件: D00291 D00291, D02235 D02235 💬 |
AVPR2 2件: AVPR2, F8 💬 |
Complement and coagulation cascades 4件: Complement and coagulation cascades, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption |
288 1件: 288 💬 |
43 |
Desipramine |
Desipramine |
2件: D00812 D00812, D07791 D07791 💬 |
SLC6A2 2件: SLC6A2, SLC6A4 💬 |
Serotonergic synapse 2件: Serotonergic synapse, Synaptic vesicle cycle |
006 4件: 6 , 17, 120, 156 💬 |
44 |
Desipramine (dmi) |
Desipramine |
2件: D00812 D00812, D07791 D07791 💬 |
SLC6A2 2件: SLC6A2, SLC6A4 💬 |
Serotonergic synapse 2件: Serotonergic synapse, Synaptic vesicle cycle |
006 2件: 6 , 17 💬 |
45 |
Desmopressin |
Desmopressin |
2件: D00291 D00291, D02235 D02235 💬 |
AVPR2 2件: AVPR2, F8 💬 |
Complement and coagulation cascades 4件: Complement and coagulation cascades, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption |
006 5件: 6 , 64, 72, 225, 288 💬 |
46 |
Desmopressin acetat |
Desmopressin |
2件: D00291 D00291, D02235 D02235 💬 |
AVPR2 2件: AVPR2, F8 💬 |
Complement and coagulation cascades 4件: Complement and coagulation cascades, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption |
006 1件: 6 💬 |
47 |
Desmopressin acetate |
Acetate |
2件: D00291 D00291, D02235 D02235 💬 |
AVPR2 2件: AVPR2, F8 💬 |
Complement and coagulation cascades 4件: Complement and coagulation cascades, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption |
064 2件: 64, 288 💬 |
48 |
Desmopressin acetate trihydrate |
Acetate |
2件: D00291 D00291, D02235 D02235 💬 |
AVPR2 2件: AVPR2, F8 💬 |
Complement and coagulation cascades 4件: Complement and coagulation cascades, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption |
225 1件: 225 💬 |
49 |
Desmopressin intranasal |
Desmopressin |
2件: D00291 D00291, D02235 D02235 💬 |
AVPR2 2件: AVPR2, F8 💬 |
Complement and coagulation cascades 4件: Complement and coagulation cascades, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption |
072 1件: 72 💬 |
50 |
Desmopressin oral melt |
Desmopressin |
2件: D00291 D00291, D02235 D02235 💬 |
AVPR2 2件: AVPR2, F8 💬 |
Complement and coagulation cascades 4件: Complement and coagulation cascades, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption |
072 1件: 72 💬 |
51 |
Device: no orthosis |
- |
- |
- |
- |
070 1件: 70 💬 |
52 |
Device: nocturnal oxygen , nocturnal bi-level positive pressure ventilation |
Oxygen |
1件: D00003 D00003 💬 |
- |
- |
299 1件: 299 💬 |
53 |
Device: non invasive ventilation |
- |
- |
- |
- |
299 1件: 299 💬 |
54 |
Device: noninvasive ventilation |
- |
- |
- |
- |
299 1件: 299 💬 |
55 |
Device: novel allergen-specific immune signature directed approach to dietary elimination therapy |
- |
- |
- |
- |
098 1件: 98 💬 |
56 |
Device: occlusive non adherent dressing |
- |
- |
- |
- |
036 1件: 36 💬 |
57 |
Device: reciprocating procedure device (rpd) - avanca re no. 1091001 |
- |
- |
- |
- |
046 1件: 46 💬 |
58 |
Dexrazoxane (drz) plus mitoxantrone (mx) |
Dexrazoxane |
3件: D02166 D02166, D03730 D03730, D08224 D08224 💬 |
TOP2A 2件: TOP2A, TOP2B 💬 |
Platinum drug resistance 1件: Platinum drug resistance |
013 1件: 13 💬 |
59 |
Diagnostic test: nociceptor flexor reflex |
- |
- |
- |
- |
149 1件: 149 💬 |
60 |
Droxidopa |
Droxidopa |
1件: D01277 D01277 💬 |
ADRA1A 9件: ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3 💬 |
AMPK signaling pathway 13件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
005 3件: 5 , 6 , 17 💬 |
61 |
Droxidopa 100 mg [northera] |
Droxidopa |
1件: D01277 D01277 💬 |
ADRA1A 9件: ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3 💬 |
AMPK signaling pathway 13件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
006 1件: 6 💬 |
62 |
Experimental (non immunosuppressive symptomatic treatment (nist) and rituximab) |
Rituximab |
1件: D02994 D02994 💬 |
MS4A1 1件: MS4A1 💬 |
Hematopoietic cell lineage 1件: Hematopoietic cell lineage |
222 1件: 222 💬 |
63 |
Extavia (interferon beta-1b), novartis pharma ag |
Human interferon beta |
1件: D00746 D00746 💬 |
IFNAR1 2件: IFNAR1, IFNAR2 💬 |
Coronavirus disease - COVID-19 18件: Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway |
013 1件: 13 💬 |
64 |
Extended-release quetiapine fumarate |
Quetiapine |
2件: D00458 D00458, D08456 D08456 💬 |
DRD2 2件: DRD2, HTR2A 💬 |
Alcoholism 11件: Alcoholism, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Serotonergic synapse, cAMP signaling pathway |
013 1件: 13 💬 |
65 |
F-a-f-a (fiasp-novorapid-fiasp-novorapid) |
- |
- |
- |
- |
299 1件: 299 💬 |
66 |
Freeze-dried sulfonated human normal immunoglobulin (ggs) |
Human immunoglobulin G |
- |
- |
- |
014 3件: 14, 43, 45 💬 |
67 |
From august 2020 'no additional treatment' |
- |
- |
- |
- |
051 1件: 51 💬 |
68 |
Ga-68-dota-noc |
- |
- |
- |
- |
084 1件: 84 💬 |
69 |
Gallium68-dota-noc |
- |
- |
- |
- |
085 1件: 85 💬 |
70 |
Gamma-secretase/notch signalling pathway inhibitor ro4929097 |
- |
- |
- |
- |
074 1件: 74 💬 |
71 |
Gelatin |
Gelatin |
2件: D00115 D00115, D06892 D06892 💬 |
- |
- |
028 4件: 28, 78, 97, 269 💬 |
72 |
Ginger |
Ginger |
1件: D06744 D06744 💬 |
- |
- |
046 1件: 46 💬 |
73 |
Glatiramer acetate 20 mg, with mitoxantrone |
Acetate |
3件: D02166 D02166, D04318 D04318, D08224 D08224 💬 |
HLA-A 22件: HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G, TOP2A, TOP2B 💬 |
Allograft rejection 33件: Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Platinum drug resistance, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis |
013 1件: 13 💬 |
74 |
Glucocorticoids (permitted,not necessary) |
- |
- |
- |
- |
046 1件: 46 💬 |
75 |
Green tea leaf |
Green tea leaf |
1件: D06903 D06903 💬 |
- |
- |
017 1件: 17 💬 |
76 |
Gsk2018682 cd3 non-micronised tablet |
- |
- |
- |
- |
013 1件: 13 💬 |
77 |
Gsk2018682 cd3 non-micronised tablet in fed state |
- |
- |
- |
- |
013 1件: 13 💬 |
78 |
Hemin |
Hemin |
1件: D10003 D10003 💬 |
ALAS1 2件: ALAS1, ALAS2 💬 |
Biosynthesis of cofactors 4件: Biosynthesis of cofactors, Glycine, serine and threonine metabolism, Metabolic pathways, Porphyrin and chlorophyll metabolism |
254 1件: 254 💬 |
79 |
Hemin for injection |
Hemin |
1件: D10003 D10003 💬 |
ALAS1 2件: ALAS1, ALAS2 💬 |
Biosynthesis of cofactors 4件: Biosynthesis of cofactors, Glycine, serine and threonine metabolism, Metabolic pathways, Porphyrin and chlorophyll metabolism |
254 1件: 254 💬 |
80 |
Human normal 10% immunoglobulin for intravenous administration |
- |
- |
- |
- |
014 1件: 14 💬 |
81 |
Human normal 10% immunoglobulin for intravenous administrationn |
- |
- |
- |
- |
014 1件: 14 💬 |
82 |
Human normal immunoglobulin |
Human immunoglobulin G |
- |
- |
- |
011 9件: 11, 13, 14, 43, 45, 50, 51, 63, 65 💬 |
83 |
Human normal immunoglobulin (iv) |
Human immunoglobulin G |
- |
- |
- |
011 4件: 11, 14, 63, 65 💬 |
84 |
Human normal immunoglobulin (ivig) |
Human immunoglobulin G |
- |
- |
- |
050 2件: 50, 65 💬 |
85 |
Human normal immunoglobulin (scig) |
Human immunoglobulin G |
- |
- |
- |
014 1件: 14 💬 |
86 |
Human normal immunoglobulin (subcutaneous - intramuscular immunoglobulin) |
Human immunoglobulin G |
- |
- |
- |
065 1件: 65 💬 |
87 |
Human normal immunoglobulin (subcutaneous) |
Human immunoglobulin G |
- |
- |
- |
065 1件: 65 💬 |
88 |
Human normal immunoglobulin for |
Human immunoglobulin G |
- |
- |
- |
065 1件: 65 💬 |
89 |
Human normal immunoglobulin for intravenous (iv) administration |
Human immunoglobulin G |
- |
- |
- |
051 1件: 51 💬 |
90 |
Human normal immunoglobulin for intravenous administration |
Human immunoglobulin G |
- |
- |
- |
014 3件: 14, 51, 65 💬 |
91 |
Human normal immunoglobulin for intravenous use |
Human immunoglobulin G |
- |
- |
- |
063 2件: 63, 65 💬 |
92 |
Human normal immunoglobulin for intravenous use (ivig) |
Human immunoglobulin G |
- |
- |
- |
065 1件: 65 💬 |
93 |
Human normal immunoglobulin for intrvenous use |
Human immunoglobulin G |
- |
- |
- |
063 1件: 63 💬 |
94 |
Human normal immunoglobulin for subcutaneous administration |
Human immunoglobulin G |
- |
- |
- |
051 2件: 51, 65 💬 |
95 |
Human normal immunoglobulin for subcutaneous administration (igsc) |
Human immunoglobulin G |
- |
- |
- |
065 1件: 65 💬 |
96 |
Human normal immunoglobulin g (igg > 98% purity) |
Human immunoglobulin G |
- |
- |
- |
014 3件: 14, 63, 65 💬 |
97 |
Human normal immunoglobulin g (igg) |
Human immunoglobulin G |
- |
- |
- |
011 1件: 11 💬 |
98 |
Human normal immunoglogulin (ivig) |
Human immunoglobulin G |
- |
- |
- |
050 1件: 50 💬 |
99 |
Human recombinant tissue non-specific alkaline phosphatase fusion protein |
Alkaline Phosphatase |
- |
- |
- |
172 1件: 172 💬 |
100 |
Immunoglobulin g1, anti (protein nogo a) (human mus musculus monoclonal heavy |
- |
- |
- |
- |
002 1件: 2 💬 |
101 |
Immunoglobulin g1, anti (protein nogo a) (human mus musculus monoclonal heavy chain), disulfide with human mus musculus monoclonal light chain, dimer |
- |
- |
- |
- |
002 1件: 2 💬 |
102 |
Immunoglobulina umana normale per somministrazione endovenosa |
- |
- |
- |
- |
014 1件: 14 💬 |
103 |
Immunoglobulins, normal human |
- |
- |
- |
- |
065 1件: 65 💬 |
104 |
Immunoglobulins, normal human, for extravascular adm. |
- |
- |
- |
- |
014 1件: 14 💬 |
105 |
Immunoglobulins, normal human, for intravascular adm. |
- |
- |
- |
- |
014 2件: 14, 15 💬 |
106 |
Inhaled nitric oxide |
Nitric Oxide |
1件: D00074 D00074 💬 |
- |
- |
085 2件: 85, 86 💬 |
107 |
Inhaled nitric oxide & inopulse delivery |
Nitric Oxide |
1件: D00074 D00074 💬 |
- |
- |
086 1件: 86 💬 |
108 |
Inhaled nitric oxide - 30 mcg/kg ibw/hr |
Nitric Oxide |
1件: D00074 D00074 💬 |
- |
- |
085 1件: 85 💬 |
109 |
Inhaled nitric oxide 5,10,15 mcg/kg ibw/hr |
Nitric Oxide |
1件: D00074 D00074 💬 |
- |
- |
085 1件: 85 💬 |
110 |
Inhaled nitric oxide 75 mcg/kg ibw/hr |
Nitric Oxide |
1件: D00074 D00074 💬 |
- |
- |
085 2件: 85, 86 💬 |
111 |
Inhaled no with pulsed delivery |
- |
- |
- |
- |
086 1件: 86 💬 |
112 |
Injection of normal saline |
- |
- |
- |
- |
006 1件: 6 💬 |
113 |
Inn not available |
- |
- |
- |
- |
019 2件: 19, 46 💬 |
114 |
Inn not available yet |
- |
- |
- |
- |
222 1件: 222 💬 |
115 |
Inn not yet proposed |
- |
- |
- |
- |
193 1件: 193 💬 |
116 |
Intravenous and oral n-acetyl cysteine |
Cysteine |
2件: D00026 D00026, D02326 D02326 💬 |
- |
- |
006 1件: 6 💬 |
117 |
Istradefylline |
Istradefylline |
1件: D04641 D04641 💬 |
ADORA2A 1件: ADORA2A 💬 |
Alcoholism 7件: Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway |
006 1件: 6 💬 |
118 |
Istradefylline ( kw-6002) |
Istradefylline |
1件: D04641 D04641 💬 |
ADORA2A 1件: ADORA2A 💬 |
Alcoholism 7件: Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway |
006 1件: 6 💬 |
119 |
Istradefylline (kw-6002) |
Istradefylline |
1件: D04641 D04641 💬 |
ADORA2A 1件: ADORA2A 💬 |
Alcoholism 7件: Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway |
006 1件: 6 💬 |
120 |
Istradefylline 20 mg |
Istradefylline |
1件: D04641 D04641 💬 |
ADORA2A 1件: ADORA2A 💬 |
Alcoholism 7件: Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway |
006 1件: 6 💬 |
121 |
Istradefylline 20 mg or 40 mg |
Istradefylline |
1件: D04641 D04641 💬 |
ADORA2A 1件: ADORA2A 💬 |
Alcoholism 7件: Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway |
006 1件: 6 💬 |
122 |
Istradefylline 40 mg |
Istradefylline |
1件: D04641 D04641 💬 |
ADORA2A 1件: ADORA2A 💬 |
Alcoholism 7件: Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway |
006 1件: 6 💬 |
123 |
Kw-6002 (istradefylline) |
Istradefylline |
1件: D04641 D04641 💬 |
ADORA2A 1件: ADORA2A 💬 |
Alcoholism 7件: Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway |
006 1件: 6 💬 |
124 |
Leflunomide (permitted, not necessary) |
Leflunomide |
1件: D00749 D00749 💬 |
DHODH 1件: DHODH 💬 |
Biosynthesis of cofactors 3件: Biosynthesis of cofactors, Metabolic pathways, Pyrimidine metabolism |
046 1件: 46 💬 |
125 |
Lenadogene nolparvovec |
- |
- |
- |
- |
302 1件: 302 💬 |
126 |
Levobupivacaine |
Levobupivacaine |
2件: D01287 D01287, D08116 D08116 💬 |
SCN1A 5件: SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 |
Adrenergic signaling in cardiomyocytes 3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
046 1件: 46 💬 |
127 |
Levonorgestrel |
Levonorgestrel |
1件: D00950 D00950 💬 |
PGR 1件: PGR 💬 |
Breast cancer 4件: Breast cancer, Estrogen signaling pathway, Oocyte meiosis, Progesterone-mediated oocyte maturation |
013 1件: 13 💬 |
128 |
Loestrin (norethindrone acetate and ethinyl estradiol) |
Acetate |
11件: D00105 D00105, D00182 D00182, D00554 D00554, D00953 D00953, D01413 D01413, D01617 D01617, D01953 D01953, D04061 D04061, D04063 D04063, D04064 D04064, D04065 D04065 💬 |
ESR1 3件: ESR1, ESR2, PGR 💬 |
Breast cancer 11件: Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Oocyte meiosis, Pathways in cancer, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway |
299 1件: 299 💬 |
129 |
Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 µg ethinyl estradiol) |
Acetate |
11件: D00105 D00105, D00182 D00182, D00554 D00554, D00953 D00953, D01413 D01413, D01617 D01617, D01953 D01953, D04061 D04061, D04063 D04063, D04064 D04064, D04065 D04065 💬 |
ESR1 3件: ESR1, ESR2, PGR 💬 |
Breast cancer 11件: Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Oocyte meiosis, Pathways in cancer, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway |
046 2件: 46, 49 💬 |
130 |
Lopinavir/ritonavir |
Lopinavir |
2件: D00427 D00427, D01425 D01425 💬 |
- |
- |
265 1件: 265 💬 |
131 |
Lopinavir/ritonavir + nevirapine |
Lopinavir |
3件: D00427 D00427, D00435 D00435, D01425 D01425 💬 |
- |
- |
265 1件: 265 💬 |
132 |
Lopinavir/ritonavir + zidovudine + lamivudine |
Lamivudine |
4件: D00353 D00353, D00413 D00413, D00427 D00427, D01425 D01425 💬 |
- |
- |
265 1件: 265 💬 |
133 |
Methotrexate(mtx) administration is at the discretion of the rheumatologist and no tradename is fixed by the protocol |
Methotrexate |
2件: D00142 D00142, D02115 D02115 💬 |
DHFR 2件: DHFR, DHFR2 💬 |
Antifolate resistance 5件: Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate |
046 1件: 46 💬 |
134 |
Methotrexate(mtx) administration is at the discretion of the rheumatologist and no tradename is fixed by the protocol. |
Methotrexate |
2件: D00142 D00142, D02115 D02115 💬 |
DHFR 2件: DHFR, DHFR2 💬 |
Antifolate resistance 5件: Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate |
046 1件: 46 💬 |
135 |
Metronidazole |
Metronidazole |
3件: D00409 D00409, D05016 D05016, D05017 D05017 💬 |
- |
- |
046 8件: 46, 51, 63, 94, 95, 96, 97, 291 💬 |
136 |
Metronidazole capsule 50 mg |
Metronidazole |
3件: D00409 D00409, D05016 D05016, D05017 D05017 💬 |
- |
- |
097 1件: 97 💬 |
137 |
Mitoxantrone |
Mitoxantrone |
2件: D02166 D02166, D08224 D08224 💬 |
TOP2A 2件: TOP2A, TOP2B 💬 |
Platinum drug resistance 1件: Platinum drug resistance |
013 1件: 13 💬 |
138 |
Monotherapy (lopinavir/ritonavir) |
Lopinavir |
2件: D00427 D00427, D01425 D01425 💬 |
- |
- |
265 1件: 265 💬 |
139 |
Monotherapy (lopinavir/ritonavir) + abc/3tc |
Lopinavir |
2件: D00427 D00427, D01425 D01425 💬 |
- |
- |
265 1件: 265 💬 |
140 |
N acetyl cysteine |
Cysteine |
2件: D00026 D00026, D02326 D02326 💬 |
- |
- |
006 2件: 6 , 19 💬 |
141 |
N-acetyl cysteine |
Cysteine |
2件: D00026 D00026, D02326 D02326 💬 |
- |
- |
013 7件: 13, 19, 34, 85, 88, 296, 310 💬 |
142 |
N-acetyl cysteine (nac) |
Cysteine |
2件: D00026 D00026, D02326 D02326 💬 |
- |
- |
090 1件: 90 💬 |
143 |
N-acetyl-cysteine |
Cysteine |
2件: D00026 D00026, D02326 D02326 💬 |
- |
- |
084 1件: 84 💬 |
144 |
Neoral soft gelatin capsules |
Gelatin |
2件: D00115 D00115, D06892 D06892 💬 |
- |
- |
097 2件: 97, 269 💬 |
145 |
Nitric oxide |
Nitric Oxide |
1件: D00074 D00074 💬 |
- |
- |
046 8件: 46, 85, 86, 98, 210, 251, 294, 299 💬 |
146 |
Nitric oxide 160 ppm |
Nitric Oxide |
1件: D00074 D00074 💬 |
- |
- |
299 1件: 299 💬 |
147 |
Nitric oxide for inhalation |
Nitric Oxide |
1件: D00074 D00074 💬 |
- |
- |
086 2件: 86, 299 💬 |
148 |
Nitric oxide generated by the geno nitrosyl delivery system |
Nitric Oxide |
1件: D00074 D00074 💬 |
- |
- |
086 1件: 86 💬 |
149 |
Nitric oxide plus oxygen |
Nitric Oxide |
2件: D00003 D00003, D00074 D00074 💬 |
- |
- |
086 1件: 86 💬 |
150 |
Nitric oxide supplement |
Nitric Oxide |
1件: D00074 D00074 💬 |
- |
- |
251 1件: 251 💬 |
151 |
No |
- |
- |
- |
- |
046 3件: 46, 62, 299 💬 |
152 |
Nolpitantium besylate |
- |
- |
- |
- |
097 1件: 97 💬 |
153 |
Nomegestrol |
Nomegestrol |
1件: D07222 D07222 💬 |
PGR 1件: PGR 💬 |
Breast cancer 4件: Breast cancer, Estrogen signaling pathway, Oocyte meiosis, Progesterone-mediated oocyte maturation |
013 1件: 13 💬 |
154 |
Nomegestrol acetate |
Acetate |
2件: D07222 D07222, D08281 D08281 💬 |
PGR 1件: PGR 💬 |
Breast cancer 4件: Breast cancer, Estrogen signaling pathway, Oocyte meiosis, Progesterone-mediated oocyte maturation |
013 1件: 13 💬 |
155 |
Non applicabile |
- |
- |
- |
- |
051 1件: 51 💬 |
156 |
Non applicable |
- |
- |
- |
- |
010 2件: 10, 19 💬 |
157 |
Non as of yet |
- |
- |
- |
- |
097 1件: 97 💬 |
158 |
Non atg conditioning regimen |
- |
- |
- |
- |
060 1件: 60 💬 |
159 |
Non propietry, therefore n/a |
- |
- |
- |
- |
051 1件: 51 💬 |
160 |
Non-anti-tnf biologics |
- |
- |
- |
- |
046 2件: 46, 271 💬 |
161 |
Non-biologic anti-rheumatic drugs |
- |
- |
- |
- |
046 1件: 46 💬 |
162 |
Non-biologic disease modifying anti-rheumatic drug (dmard) |
- |
- |
- |
- |
046 1件: 46 💬 |
163 |
Non-biologic dmards |
- |
- |
- |
- |
046 2件: 46, 86 💬 |
164 |
Non-biological dmard's |
- |
- |
- |
- |
046 1件: 46 💬 |
165 |
Non-biological dmards |
- |
- |
- |
- |
046 1件: 46 💬 |
166 |
Non-myeloablative hematopoietic stem cell transplantation |
- |
- |
- |
- |
093 1件: 93 💬 |
167 |
Non-nucleoside reverse transcriptase inhibitors |
- |
- |
- |
- |
265 1件: 265 💬 |
168 |
Non-pegylated interferon |
- |
- |
- |
- |
013 1件: 13 💬 |
169 |
Non-steroidal anti-inflammatory drug |
- |
- |
- |
- |
046 1件: 46 💬 |
170 |
Non-steroidal anti-inflammatory drug (nsaid) |
- |
- |
- |
- |
046 1件: 46 💬 |
171 |
Non-steroidal anti-inflammatory drugs |
- |
- |
- |
- |
046 1件: 46 💬 |
172 |
Non-steroidal anti-inflammatory drugs (nsaids) |
- |
- |
- |
- |
107 1件: 107 💬 |
173 |
Nonbiologic dmards of investigator's choice |
- |
- |
- |
- |
046 1件: 46 💬 |
174 |
None |
- |
- |
- |
- |
046 14件: 46, 65, 78, 84, 85, 96, 97, 140, 160, 161, 171, 231, 271, 299 💬 |
175 |
None as of yet |
- |
- |
- |
- |
046 1件: 46 💬 |
176 |
None assigned |
- |
- |
- |
- |
231 2件: 231, 299 💬 |
177 |
None at this time |
- |
- |
- |
- |
096 2件: 96, 140 💬 |
178 |
None given |
- |
- |
- |
- |
097 1件: 97 💬 |
179 |
Nordiflex |
- |
- |
- |
- |
078 1件: 78 💬 |
180 |
Nordilet® |
- |
- |
- |
- |
078 1件: 78 💬 |
181 |
Norditropin |
- |
- |
- |
- |
078 1件: 78 💬 |
182 |
Norditropin 24 iu |
- |
- |
- |
- |
195 1件: 195 💬 |
183 |
Norditropin flexpro 10 mg |
- |
- |
- |
- |
078 1件: 78 💬 |
184 |
Norditropin flexpro 10 mg/1.5 ml |
- |
- |
- |
- |
078 1件: 78 💬 |
185 |
Norditropin growth hormone |
Somatotropin |
1件: D02691 D02691 💬 |
GHR 1件: GHR 💬 |
Cytokine-cytokine receptor interaction 5件: Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
078 1件: 78 💬 |
186 |
Norditropin nordiflex® |
- |
- |
- |
- |
078 1件: 78 💬 |
187 |
Norditropin nordiflex® 10 mg/1.5 ml |
- |
- |
- |
- |
078 1件: 78 💬 |
188 |
Norditropin nordiflex® 10mg/1.5 ml |
- |
- |
- |
- |
078 1件: 78 💬 |
189 |
Norditropin simplex |
- |
- |
- |
- |
078 1件: 78 💬 |
190 |
Norditropin simplexx |
- |
- |
- |
- |
003 4件: 3 , 78, 193, 195 💬 |
191 |
Norditropin simplexx (5mg/1,5 ml) (inn:somatropin) |
Somatotropin |
1件: D02691 D02691 💬 |
GHR 1件: GHR 💬 |
Cytokine-cytokine receptor interaction 5件: Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
078 1件: 78 💬 |
192 |
Norditropin simplexx (growth hormone) |
Somatotropin |
1件: D02691 D02691 💬 |
GHR 1件: GHR 💬 |
Cytokine-cytokine receptor interaction 5件: Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
078 1件: 78 💬 |
193 |
Norditropin simplexx 10 mg |
- |
- |
- |
- |
078 1件: 78 💬 |
194 |
Norditropin simplexx 15 mg/1.5 ml |
- |
- |
- |
- |
003 1件: 3 💬 |
195 |
Norditropin simplexx 5mg/1.5ml |
- |
- |
- |
- |
078 1件: 78 💬 |
196 |
Norditropin® |
- |
- |
- |
- |
078 1件: 78 💬 |
197 |
Norditropin® flexpro® |
- |
- |
- |
- |
078 1件: 78 💬 |
198 |
Norditropin® flexpro® pen |
- |
- |
- |
- |
078 1件: 78 💬 |
199 |
Norditropin® simplexx® 5 mg/1.5ml |
- |
- |
- |
- |
078 1件: 78 💬 |
200 |
Norepinephrine |
Norepinephrine |
2件: D00076 D00076, D05206 D05206 💬 |
ADRA1A 9件: ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3 💬 |
AMPK signaling pathway 13件: AMPK signaling pathway, Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, Thermogenesis, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
022 1件: 22 💬 |
201 |
Norethindrone |
Norethisterone |
2件: D00182 D00182, D00953 D00953 💬 |
PGR 1件: PGR 💬 |
Breast cancer 4件: Breast cancer, Estrogen signaling pathway, Oocyte meiosis, Progesterone-mediated oocyte maturation |
013 4件: 13, 46, 49, 299 💬 |
202 |
Norgestimate |
Norgestimate |
1件: D05209 D05209 💬 |
PGR 1件: PGR 💬 |
Breast cancer 4件: Breast cancer, Estrogen signaling pathway, Oocyte meiosis, Progesterone-mediated oocyte maturation |
299 1件: 299 💬 |
203 |
Normal human immunoglobulin g |
Human immunoglobulin G |
- |
- |
- |
065 1件: 65 💬 |
204 |
Normal saline |
- |
- |
- |
- |
006 16件: 6 , 17, 22, 36, 46, 49, 60, 70, 94, 96, 210, 211, 226, 276, 296, 299 💬 |
205 |
Normal saline 0.9% infusion solution |
- |
- |
- |
- |
022 1件: 22 💬 |
206 |
Normal saline enema |
- |
- |
- |
- |
097 1件: 97 💬 |
207 |
Normal saline for injection |
- |
- |
- |
- |
013 1件: 13 💬 |
208 |
Normal saline instillation |
- |
- |
- |
- |
226 1件: 226 💬 |
209 |
Normal saline iv, salt tablets |
- |
- |
- |
- |
299 1件: 299 💬 |
210 |
Normal saline solution |
- |
- |
- |
- |
299 1件: 299 💬 |
211 |
Normal saline: |
- |
- |
- |
- |
299 1件: 299 💬 |
212 |
Normix |
- |
- |
- |
- |
096 1件: 96 💬 |
213 |
Normix*ad 12cpr riv 200mg |
- |
- |
- |
- |
096 1件: 96 💬 |
214 |
Norspan |
- |
- |
- |
- |
046 1件: 46 💬 |
215 |
Northera |
- |
- |
- |
- |
006 1件: 6 💬 |
216 |
Nortriptyline |
Nortriptyline |
2件: D00816 D00816, D08288 D08288 💬 |
SLC6A2 2件: SLC6A2, SLC6A4 💬 |
Serotonergic synapse 2件: Serotonergic synapse, Synaptic vesicle cycle |
006 2件: 6 , 226 💬 |
217 |
Nortriptyline hydrochloride |
Nortriptyline |
2件: D00816 D00816, D08288 D08288 💬 |
SLC6A2 2件: SLC6A2, SLC6A4 💬 |
Serotonergic synapse 2件: Serotonergic synapse, Synaptic vesicle cycle |
006 1件: 6 💬 |
218 |
Norudca |
- |
- |
- |
- |
094 1件: 94 💬 |
219 |
Norursodeoxycholic acid |
norUrsodeoxycholic acid |
- |
- |
- |
094 1件: 94 💬 |
220 |
Norvir |
- |
- |
- |
- |
265 2件: 265, 299 💬 |
221 |
Norvir 100 mg film-coated tablets |
- |
- |
- |
- |
299 1件: 299 💬 |
222 |
Novamin |
- |
- |
- |
- |
299 1件: 299 💬 |
223 |
Novantrone |
- |
- |
- |
- |
013 1件: 13 💬 |
224 |
Novantrone*inf 2mg/ml 5ml |
- |
- |
- |
- |
013 1件: 13 💬 |
225 |
Novartis pharmaceuticals corporation |
- |
- |
- |
- |
013 1件: 13 💬 |
226 |
Novatrex |
- |
- |
- |
- |
013 1件: 13 💬 |
227 |
Novo rapid |
- |
- |
- |
- |
299 1件: 299 💬 |
228 |
Novo rapid insulin (novonordisk) |
- |
- |
- |
- |
299 1件: 299 💬 |
229 |
Novolin-r insulin |
- |
- |
- |
- |
127 1件: 127 💬 |
230 |
Novolog insulin |
- |
- |
- |
- |
299 1件: 299 💬 |
231 |
Novonorm 0.5 mg |
- |
- |
- |
- |
299 1件: 299 💬 |
232 |
Novonorm 1 mg |
- |
- |
- |
- |
299 1件: 299 💬 |
233 |
Novonorm 2 mg |
- |
- |
- |
- |
299 1件: 299 💬 |
234 |
Novorapid / humalog short acting insulin |
- |
- |
- |
- |
299 1件: 299 💬 |
235 |
Novorapid 100 u/ml, solution for injection in a vial. novorapid penfill 100 u/ml, solution for injection in a cartridge. novorapid flexpen 100 u/ml, solution for injection in a pre-filled pen. |
- |
- |
- |
- |
299 1件: 299 💬 |
236 |
Novorapid aspartate |
- |
- |
- |
- |
299 1件: 299 💬 |
237 |
Nox-e36 |
- |
- |
- |
- |
049 1件: 49 💬 |
238 |
Noxafil |
- |
- |
- |
- |
060 3件: 60, 65, 299 💬 |
239 |
Noxafil - 40 mg/ml sospensione orale uso orale flacone (vetro) 105 ml 1 flacone |
- |
- |
- |
- |
299 1件: 299 💬 |
240 |
Noxafil - oral suspension 40 mg/ml |
- |
- |
- |
- |
299 1件: 299 💬 |
241 |
Noxafil 100 mg |
- |
- |
- |
- |
299 1件: 299 💬 |
242 |
Noxafil 40 mg/ml oral solution |
- |
- |
- |
- |
065 1件: 65 💬 |
243 |
Noxafil gastro resistant tablets |
- |
- |
- |
- |
060 1件: 60 💬 |
244 |
Noxafil® |
- |
- |
- |
- |
060 2件: 60, 299 💬 |
245 |
Nsaids (permitted,not necessary) |
- |
- |
- |
- |
046 1件: 46 💬 |
246 |
Ortho-cyclen, ethinyl estradiol/norgestimate, 0.035 mg/0.250 mg |
Estradiol |
10件: D00105 D00105, D00554 D00554, D01413 D01413, D01617 D01617, D01953 D01953, D04061 D04061, D04063 D04063, D04064 D04064, D04065 D04065, D05209 D05209 💬 |
ESR1 3件: ESR1, ESR2, PGR 💬 |
Breast cancer 11件: Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Oocyte meiosis, Pathways in cancer, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway |
299 1件: 299 💬 |
247 |
Ortho-novum |
- |
- |
- |
- |
046 2件: 46, 49 💬 |
248 |
Ortho-novum 777 |
- |
- |
- |
- |
049 1件: 49 💬 |
249 |
Ortho-novum® 1/35 |
- |
- |
- |
- |
046 1件: 46 💬 |
250 |
Other non steroidal anti-inflammatory drugs (nsaids) except etodolac |
Etodolac |
1件: D00315 D00315 💬 |
PTGS2 1件: PTGS2 💬 |
Alzheimer disease 22件: Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway |
046 1件: 46 💬 |
251 |
Other non-selective nsaids |
- |
- |
- |
- |
271 1件: 271 💬 |
252 |
Other non-sponsor pancreatic enzyme replacement therapy |
- |
- |
- |
- |
299 1件: 299 💬 |
253 |
Other: antigen (wheat base soy sauce) spray |
Wheat |
1件: D06902 D06902 💬 |
- |
- |
098 1件: 98 💬 |
254 |
Other: control group(normal saline) |
- |
- |
- |
- |
097 1件: 97 💬 |
255 |
Other: dietary intervention with no-carrageenan diet |
- |
- |
- |
- |
097 1件: 97 💬 |
256 |
Other: fractional exhaled no (feno) |
- |
- |
- |
- |
096 1件: 96 💬 |
257 |
Other: mitoxantrone - immunomodulator |
Mitoxantrone |
2件: D02166 D02166, D08224 D08224 💬 |
TOP2A 2件: TOP2A, TOP2B 💬 |
Platinum drug resistance 1件: Platinum drug resistance |
013 1件: 13 💬 |
258 |
Other: no active treatment |
- |
- |
- |
- |
274 1件: 274 💬 |
259 |
Other: no anti-inflammatory treatment |
- |
- |
- |
- |
271 1件: 271 💬 |
260 |
Other: no device |
- |
- |
- |
- |
013 1件: 13 💬 |
261 |
Other: no doxycycline |
Doxycycline |
5件: D00307 D00307, D02129 D02129, D03903 D03903, D03904 D03904, D07876 D07876 💬 |
- |
- |
299 1件: 299 💬 |
262 |
Other: no enzyme therapy |
- |
- |
- |
- |
298 1件: 298 💬 |
263 |
Other: no intervention |
- |
- |
- |
- |
070 1件: 70 💬 |
264 |
Other: no intervention: standard of care |
- |
- |
- |
- |
085 1件: 85 💬 |
265 |
Other: no it treatment |
- |
- |
- |
- |
019 1件: 19 💬 |
266 |
Other: no msdmds therapy (control) |
- |
- |
- |
- |
013 1件: 13 💬 |
267 |
Other: no pancreatic enzyme replacement therapy |
- |
- |
- |
- |
299 1件: 299 💬 |
268 |
Other: no plasma exchange |
- |
- |
- |
- |
043 2件: 43, 44 💬 |
269 |
Other: no treatment |
- |
- |
- |
- |
053 2件: 53, 256 💬 |
270 |
Other: no treatment arm |
- |
- |
- |
- |
013 1件: 13 💬 |
271 |
Other: no treatment given |
- |
- |
- |
- |
078 1件: 78 💬 |
272 |
Other: non impact aerobics |
- |
- |
- |
- |
013 1件: 13 💬 |
273 |
Other: non-hormonal period |
- |
- |
- |
- |
299 1件: 299 💬 |
274 |
Other: non-motor symptoms |
- |
- |
- |
- |
006 1件: 6 💬 |
275 |
Other: noninvasive actigraphy monitor |
Methamidophos |
- |
- |
- |
086 1件: 86 💬 |
276 |
Other: nordic walking (only osteoporosis group) |
- |
- |
- |
- |
006 1件: 6 💬 |
277 |
Other: normal (control) diet |
- |
- |
- |
- |
240 1件: 240 💬 |
278 |
Other: normal diet |
- |
- |
- |
- |
096 1件: 96 💬 |
279 |
Other: normal saline |
- |
- |
- |
- |
013 4件: 13, 222, 226, 280 💬 |
280 |
Other: normal saline for injection |
- |
- |
- |
- |
084 1件: 84 💬 |
281 |
Other: oral nitric oxide testing |
Nitric Oxide |
1件: D00074 D00074 💬 |
- |
- |
098 1件: 98 💬 |
282 |
Other: sham (no implant) |
- |
- |
- |
- |
090 1件: 90 💬 |
283 |
Other: sterile normal saline (0.9% nacl) |
- |
- |
- |
- |
231 1件: 231 💬 |
284 |
Other: wheat flour |
Wheat |
1件: D06902 D06902 💬 |
- |
- |
266 1件: 266 💬 |
285 |
Patients' existing non-steroidal anti-inflammatory drug (nsaid) at approved doses |
- |
- |
- |
- |
046 1件: 46 💬 |
286 |
Pk-merz® 200mg/500ml inj(amantadine) , normal saline 500ml inj |
Amantadine |
2件: D00777 D00777, D07441 D07441 💬 |
GRIN1 5件: GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2D 💬 |
Alcoholism 20件: Alcoholism, Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Calcium signaling pathway, Circadian entrainment, Cocaine addiction, Dopaminergic synapse, Glutamatergic synapse, Huntington disease, Long-term potentiation, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases, Prion disease, Rap1 signaling pathway, Ras signaling pathway, Spinocerebellar ataxia, Systemic lupus erythematosus, cAMP signaling pathway |
006 1件: 6 💬 |
287 |
Posaconazole |
Posaconazole |
1件: D02555 D02555 💬 |
- |
- |
060 3件: 60, 65, 299 💬 |
288 |
Posaconazole (psz) |
Posaconazole |
1件: D02555 D02555 💬 |
- |
- |
065 1件: 65 💬 |
289 |
Prednison 5, 20 léciva por. tablet nob |
- |
- |
- |
- |
050 1件: 50 💬 |
290 |
Prednison 5, 20 léciva por. tablet nob. |
- |
- |
- |
- |
050 1件: 50 💬 |
291 |
Procedure: alcohol wipes vs. no alcohol wipes |
Ethanol |
4件: D00068 D00068, D02798 D02798, D04855 D04855, D06542 D06542 💬 |
- |
- |
013 1件: 13 💬 |
292 |
Procedure: audiological and ear, nose and throat examination |
- |
- |
- |
- |
078 1件: 78 💬 |
293 |
Procedure: exhaled nitric oxide |
Nitric Oxide |
1件: D00074 D00074 💬 |
- |
- |
299 1件: 299 💬 |
294 |
Procedure: exhaled nitric oxide assessment |
Nitric Oxide |
1件: D00074 D00074 💬 |
- |
- |
046 1件: 46 💬 |
295 |
Procedure: iv deployment of csvf in sterile normal saline iv solution |
- |
- |
- |
- |
085 2件: 85, 229 💬 |
296 |
Procedure: large bore (19g) histologic needle biopsy of the mediastinal lymph nodes |
- |
- |
- |
- |
084 1件: 84 💬 |
297 |
Procedure: no celiac block |
- |
- |
- |
- |
298 1件: 298 💬 |
298 |
Procedure: no gas |
- |
- |
- |
- |
086 2件: 86, 88 💬 |
299 |
Procedure: non-myeloablative high dose immunosuppressive therapy conditioning (hdit) |
- |
- |
- |
- |
049 1件: 49 💬 |
300 |
Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation |
- |
- |
- |
- |
028 6件: 28, 51, 60, 62, 65, 285 💬 |
301 |
Quetiapine |
Quetiapine |
2件: D00458 D00458, D08456 D08456 💬 |
DRD2 2件: DRD2, HTR2A 💬 |
Alcoholism 11件: Alcoholism, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Serotonergic synapse, cAMP signaling pathway |
006 2件: 6 , 13 💬 |
302 |
Rebif new formulation non titrated |
- |
- |
- |
- |
013 1件: 13 💬 |
303 |
Recombinant human somatotropin |
Somatotropin |
1件: D02691 D02691 💬 |
GHR 1件: GHR 💬 |
Cytokine-cytokine receptor interaction 5件: Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
078 2件: 78, 236 💬 |
304 |
Regular novolin r |
- |
- |
- |
- |
006 1件: 6 💬 |
305 |
Rhgh norditropin® flexpro® pen (34 µg/kg) |
Somatotropin |
1件: D02691 D02691 💬 |
GHR 1件: GHR 💬 |
Cytokine-cytokine receptor interaction 5件: Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
078 1件: 78 💬 |
306 |
Rifampicin |
Rifampicin |
1件: D00211 D00211 💬 |
- |
- |
006 5件: 6 , 17, 46, 93, 299 💬 |
307 |
Rifampin 300mg bid + istradefylline 40mg day 8 only |
Istradefylline |
2件: D00211 D00211, D04641 D04641 💬 |
ADORA2A 1件: ADORA2A 💬 |
Alcoholism 7件: Alcoholism, Calcium signaling pathway, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, Vascular smooth muscle contraction, cAMP signaling pathway |
006 1件: 6 💬 |
308 |
Ritonavir |
Ritonavir |
1件: D00427 D00427 💬 |
- |
- |
002 3件: 2 , 86, 265 💬 |
309 |
Ritonavir (norvir) |
Ritonavir |
1件: D00427 D00427 💬 |
- |
- |
265 1件: 265 💬 |
310 |
Rokan (r) novo 120 mg |
- |
- |
- |
- |
018 1件: 18 💬 |
311 |
Ropivacaine plus normal saline |
Ropivacaine |
2件: D04048 D04048, D08490 D08490 💬 |
SCN1A 5件: SCN1A, SCN2A, SCN3A, SCN5A, SCN9A 💬 |
Adrenergic signaling in cardiomyocytes 3件: Adrenergic signaling in cardiomyocytes, Dopaminergic synapse, Taste transduction |
070 1件: 70 💬 |
312 |
Saquinavir and ritonavir |
Ritonavir |
3件: D00427 D00427, D00429 D00429, D01160 D01160 💬 |
- |
- |
086 1件: 86 💬 |
313 |
Sativex oromucosal spray (non-marketed) |
- |
- |
- |
- |
013 1件: 13 💬 |
314 |
Somatotropin |
Somatotropin |
1件: D02691 D02691 💬 |
GHR 1件: GHR 💬 |
Cytokine-cytokine receptor interaction 5件: Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
003 3件: 3 , 78, 236 💬 |
315 |
Sterile normal saline (0.9% nacl) |
- |
- |
- |
- |
062 3件: 62, 234, 254 💬 |
316 |
Sterile normal saline for intravenous use |
- |
- |
- |
- |
085 2件: 85, 229 💬 |
317 |
Systemic non-biological treatments |
- |
- |
- |
- |
046 2件: 46, 271 💬 |
318 |
Tafamidis meglumine 20 mg soft gelatin capsules |
Gelatin |
4件: D00115 D00115, D01796 D01796, D06892 D06892, D09673 D09673 💬 |
TTR 1件: TTR 💬 |
Thyroid hormone synthesis 1件: Thyroid hormone synthesis |
028 1件: 28 💬 |
319 |
Tafamidis meglumine 20mg soft gelatin capsule (clinical trial image) |
Gelatin |
4件: D00115 D00115, D01796 D01796, D06892 D06892, D09673 D09673 💬 |
TTR 1件: TTR 💬 |
Thyroid hormone synthesis 1件: Thyroid hormone synthesis |
028 1件: 28 💬 |
320 |
Tafamidis meglumine 20mg soft gelatin capsule (commerical image) |
Gelatin |
4件: D00115 D00115, D01796 D01796, D06892 D06892, D09673 D09673 💬 |
TTR 1件: TTR 💬 |
Thyroid hormone synthesis 1件: Thyroid hormone synthesis |
028 1件: 28 💬 |
321 |
Takecab tablets + amoxicillin + clarithromycin (first-line eradication) takecab tablets + amoxicillin + metronidazole (second-line eradication) |
Amoxicillin |
7件: D00229 D00229, D00276 D00276, D00409 D00409, D02925 D02925, D05016 D05016, D05017 D05017, D07452 D07452 💬 |
- |
- |
063 1件: 63 💬 |
322 |
Tamoxifen |
Tamoxifen |
2件: D00966 D00966, D08559 D08559 💬 |
ESR1 2件: ESR1, ESR2 💬 |
Breast cancer 9件: Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway |
002 4件: 2 , 86, 113, 227 💬 |
323 |
Tamoxifen 20mg hexal® filmtabletten |
Tamoxifen |
2件: D00966 D00966, D08559 D08559 💬 |
ESR1 2件: ESR1, ESR2 💬 |
Breast cancer 9件: Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway |
113 1件: 113 💬 |
324 |
Tamoxifen 40 mg daily for one year |
Tamoxifen |
2件: D00966 D00966, D08559 D08559 💬 |
ESR1 2件: ESR1, ESR2 💬 |
Breast cancer 9件: Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway |
002 1件: 2 💬 |
325 |
Tamoxifen citrate |
Tamoxifen |
2件: D00966 D00966, D08559 D08559 💬 |
ESR1 2件: ESR1, ESR2 💬 |
Breast cancer 9件: Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, GnRH secretion, Pathways in cancer, Prolactin signaling pathway, Proteoglycans in cancer, Thyroid hormone signaling pathway |
113 1件: 113 💬 |
326 |
The investigational medicinal product (imp) may be labelled as either pf-04236921 106 mg/vial, clonal sc lyophilized form” or pf-04236921 powder for injection, 106 mg/vial”. supplies labelled with either nomenclature are equivalent. |
- |
- |
- |
- |
096 1件: 96 💬 |
327 |
There is no recommended inn |
- |
- |
- |
- |
065 1件: 65 💬 |
328 |
Tnf-a antagonists, non-tnfs, dmard non-biologics |
- |
- |
- |
- |
046 2件: 46, 271 💬 |
329 |
Topotecan |
Topotecan |
2件: D02168 D02168, D08618 D08618 💬 |
- |
- |
025 1件: 25 💬 |
330 |
Triamcinolone acetonide and normal saline solution |
Triamcinolone |
5件: D00385 D00385, D00983 D00983, D00984 D00984, D00985 D00985, D06216 D06216 💬 |
NR3C1 1件: NR3C1 💬 |
Neuroactive ligand-receptor interaction 1件: Neuroactive ligand-receptor interaction |
070 1件: 70 💬 |
331 |
Ustekinumab iv - nonresponder - ustekinumab 90mg sc (mp) |
Ustekinumab |
1件: D09214 D09214 💬 |
IL12A 3件: IL12A, IL12B, IL23A 💬 |
African trypanosomiasis 26件: African trypanosomiasis, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus |
096 1件: 96 💬 |
332 |
Wheat |
Wheat |
1件: D06902 D06902 💬 |
- |
- |
098 2件: 98, 266 💬 |
333 |
Zofran - no intubation |
- |
- |
- |
- |
098 1件: 98 💬 |